Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients.
Little is known about the effects of dietary supplementation on platelet survival with low doses of n-3 and n-6 fatty acids in patients with hypercholesterolemia. The effects of a 6-week intervention with fish oil capsules (daily intake: 216 mg eicosapentaenoic acid, 140 mg docosahexaenoic acid, 390 mg gamma-linolenic acid, and 3480 mg linoleic acid) on in vivo platelet survival (111 In-oxine labeled platelets) and on ex vivo markers of platelet activation were investigated in a placebo-controlled, double-blind study with 26 hypercholesterolemic patients. In vivo platelet survival increased in the fish oil group (T) from a mean of 159+/-14 hours to a mean of 164+/-12 hours (p=0.025), whereas it remained unchanged in the placebo (P) group (T vs. P; p=0.055). Ex vivo, thromboxane B2 decreased from a mean of 225+/-16 to 212+/-21 ng/mL (p=0.003) in T but did not change in P (T vs. P: p=0.002). Malondialdehyde formation was lowered significantly by fish oil supplementation from a mean of 5.49+/-1.3 to 5.12+/-1.05 nM/10(9) platelets, p=0.005, as compared with P (T vs. P; p=0.018). The trendwise decrease in 11-DH-thromboxane B2 plasma levels was not significant nor was the increase in platelet sensitivity to prostaglandin I2 by fish oil. Baseline platelet survival in patients with hyperlipoproteinemia type IIa was not different from those with hyperlipoproteinemia IIb and response to treatment in terms of platelet activation markers was not either. The changes in platelet activation parameters in T were associated with significant reductions in cholesterol (-2.9%), low density lipoprotein cholesterol (-3.5%), and triglycerides (-12.4%). Both ex vivo and in vivo platelet activation parameters exhibited signs of decreased activation by a 6-week diet supplemented with n-3 and n-6 fatty acids, which might be beneficial in reducing atherothrombotic risk, in patients with hyperlipoproteinemia type IIa and IIb.
Pirich
C
C
Department of Nuclear Medicine, University of Vienna, Austria.
Gaszo
A
A
Granegger
S
S
Sinzinger
H
H
D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects; D003131:Combined Modality Therapy; D004032:Diet; D015930:Diet Records; D018752:Diet, Fat-Restricted; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011464:Epoprostenol / Q000494:pharmacology; D005228:Fatty Acids, Essential / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005395:Fish Oils / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D019787:Linoleic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008041:Linoleic Acids; D015227:Lipid Peroxidation / Q000187:drug effects; D008074:Lipoproteins / Q000032:analysis; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D031665:Oenothera biennis; D010938:Plant Oils; D015539:Platelet Activation / Q000187:drug effects; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000097:blood; D017965:gamma-Linolenic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D005228:Fatty Acids, Essential; D005231:Fatty Acids, Unsaturated; D005395:Fish Oils; D008041:Linoleic Acids; D008074:Lipoproteins; D010938:Plant Oils; C028498:evening primrose oil; D008315:Malondialdehyde; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D017965:gamma-Linolenic Acid; D019787:Linoleic Acid; D015118:Eicosapentaenoic Acid; D011464:Epoprostenol; C026219:docosapentaenoic acid